Diagnosis of Sleep Disordered Breathing in Adults and Children
Customize your policy alerts
Sign up for fallon_community_health_plan_inc Policy SLP012013 alerts
Get alerted when Policy SLP012013 changes without checking for updates manually.
Monitor payer policy activity
Guideline governing when diagnostic sleep tests (HSAT, attended PSG, split‑night, titration) are considered medically necessary for Fallon Community Health Plan members, including adults and children; applies to ordering providers and interpreting sleep physicians.
Modified criteria for diagnostic testing for Hypoglossal Nerve Stimulation (HNS) implantation to allow PSG or HSAT performed for determining candidacy.
Added diagnostic evaluation criteria for HNS implantation in members with Down Syndrome younger than 18 years.
Added new pediatric indications for sleep testing: evaluation of hypersomnia, suspected narcolepsy (with MSLT), suspected restless leg syndrome, and suspected periodic limb movement disorder.
Reorganized pediatric in-facility initial full-night PAP titration into separate sections for initial full-night titration and full-night re-titration (CPTs 95783, 95811).
Divided the policy's medical guideline content into separate sections for adults and children.
Coverage Criteria for Diagnostic Sleep Testing
Home Sleep Apnea Test (HSAT) — Medical Necessity
HSAT meets medical necessity when ALL of the following are met (A AND B AND C AND D):
See Signs and Symptoms section for lists
Also excludes secondary sleep disorders listed (e.g., PLMD ≥15/hr with arousals not associated with respiratory events, complex parasomnias, narcolepsy after OSA treated, central sleep apnea >50% events and ≥5/hr, CNS disorders increasing CSA risk, uncontrolled nocturnal seizures)
Attended Polysomnography (PSG) — Medical Necessity
Attended PSG (95808, 95810) meets medical necessity when the patient presents with (A AND B) OR (A AND C) OR D:
Pathways
- A and B: A: Signs/symptoms of sleep-disordered breathing (witnessed apnea OR at least one sign/symptom from Category A AND one sign/symptom from Category B). B: Presence of comorbid medical conditions necessitating attended monitoring (examples: moderate–severe COPD/interstitial lung disease or chronic oxygen use; severe persistent asthma on daily oral corticosteroids or immunomodulators/biologics; moderate–severe heart failure NYHA III/IV or EF ≤40%; moderate–severe pulmonary hypertension >40 mm Hg; neuromuscular disorders causing hypoventilation; uncontrolled/refractory arrhythmias; chronic opioid use; obesity hypoventilation syndrome).
- A and C: C: Recent HSAT (<1 year) confirmed non-diagnostic (technically inadequate with valid retest attempt, or failure to establish diagnosis in a high pretest probability patient).
- D: Presence of a secondary concomitant or associated sleep disorder other than suspected OSA that may necessitate attended monitoring (e.g., PLMD ≥15/hr with arousals not associated with respiratory events; complex parasomnias with potentially injurious behavior; narcolepsy/idiopathic hypersomnia after OSA evaluated and effectively treated; central sleep apnea >50% of events and ≥5/hr; CNS disorders increasing CSA risk; uncontrolled nocturnal seizures).
See exclusions list for PSG/HSAT not medically necessary indications.
Full-Night Attended PAP Titration — Medical Necessity
Full-night attended PAP titration (95811) meets medical necessity when (A AND B) OR (A AND C) OR (A AND D); unattended APAP (E0601) meets medical necessity only when A is met and B, C, and D are not.
Unattended titration (E0601) allowed only if A met and B, C, D are not met.
Split-Night Sleep Study — Medical Necessity
Facility-based split-night study (95811) meets medical necessity when (A AND B) OR (A AND C) OR (A AND D) are present:
No minimum HSAT recording time required for diagnostic classification.
Repeat Diagnostic Testing — Medical Necessity
Repeat PSG, HSAT, or split-night meets medical necessity when the patient meets the previously stated criteria for that diagnostic test AND at least ONE of the following is present:
Repeat diagnostic PSG/HSAT/Split Night Study
Covered when the patient meets previously stated criteria for a diagnostic study AND at least ONE of the following is met:
Repeat attended PAP titration (in-lab 95811)
A repeat in‑lab PAP titration (95811) meets medical necessity for a patient with known OSA when (1 AND 2) OR 3 are met:
If prior diagnostic test unavailable, physician attestation confirming OSA may be accepted.
MSLT and MWT
MSLT and MWT are covered for evaluation of persistent daytime sleepiness or when safety is a concern:
MSLT should follow PSG/ in‑lab titration and not after split‑night study
MWT may be standalone
Diagnostic testing for Hypoglossal Nerve Stimulation (HNS) implantation (adults and adolescents)
Attended sleep study (PSG) or HSAT is medically necessary prior to Hypoglossal Nerve Stimulation (HNS) implantation when ALL criteria are met:
Policy updated to explicitly allow HSAT in addition to PSG for HNS candidacy
Pediatric‑specific HNS criteria added
Pediatric PSG and PAP titration criteria
Pediatric in‑facility PSG is covered for children <18 when specific symptoms or indications are present; PAP titration is covered when diagnostic thresholds or follow‑up needs are met:
Expanded pediatric indications include hypersomnia, suspected narcolepsy, RLS, PLMD
Pediatric titration sections reorganized into initial and re‑titration
Experimental/Investigational tests (Not medically necessary)
These diagnostic tests are considered experimental or investigational and not medically necessary for OSA diagnosis.
Coverage criteria for diagnostic testing
Covered when ALL of the following are met for OSA diagnosis or other specific conditions per Medicare guidance:
Type I–IV device rules apply
See device channel requirements
Home testing is limited to OSA diagnosis
Positive test criteria required for split‑night titration
Not covered: Polysomnography or MSLT exclusions
Polysomnography or MSLT are explicitly not covered in the following situations:
Each numbered item is an explicit exclusion for polysomnography/MSLT
Actigraphy and device definitions
Actigraphy and device classification coverage notes
Operational payment restriction and use prior to MSLT
Used to interpret appropriate test type selection
Program exceptions
Program‑specific application
Program exception
Program exception
Updated Covered Diagnostic Criteria (high-level)
Covered diagnostic evaluations (high‑level changes noted):
Policy modified to explicitly allow HSAT in addition to PSG for HNS candidacy
New pediatric indications added
Overnight oximetry alone does not meet medical necessity for screening or diagnosis of obstructive sleep apnea (OSA). Attended polysomnography (PSG) and home sleep apnea testing (HSAT) are explicitly not medically necessary for a number of listed indications including diagnosis of chronic insomnia, circadian rhythm disorders, restless legs syndrome without a covered indication, seizures in the absence of sleep disorder signs, depression/psychiatric disorders alone, snoring without daytime sleepiness, screening asymptomatic patients, and employer/government-mandated testing when no OSA symptoms are present. These exclusions are intended to prevent inappropriate use of PSG/HSAT and align testing with clinical indications that can alter management.
Home Sleep Apnea Testing (HSAT) is not considered medically necessary for pediatric patients under age 18. The policy states that the evidence is insufficient to support HSAT use in children, and therefore in-facility polysomnography is the preferred diagnostic modality for pediatric indications identified elsewhere in the policy.
Polysomnography for the evaluation of chronic insomnia is not covered. The policy follows Medicare guidance that PSG is not reasonable and necessary for chronic insomnia and lists several other explicit non-covered situations (see exclusions) where neither PSG nor MSLT should be used because they will not inform management.
Polysomnography or a Multiple Sleep Latency Test (MSLT) is not covered for nine specific clinical scenarios, including: preoperative evaluation for certain upper airway procedures without clinical evidence of OSA; diagnosis of chronic lung disease when oximetry is adequate; when seizure disorders have not been ruled out; uncomplicated non-injurious parasomnias with a clear diagnosis; epilepsy without sleep complaints; PLMD/RLS when not related to a covered indication; insomnia related to depression; circadian rhythm sleep disorders; and other situations listed in the exclusions. Documentation must support that testing is not being requested for one of these excluded indications.
References and criteria that were not applicable to diagnosis of sleep-disordered breathing for patients older than ten years have been removed except where historically required. The policy update clarifies and reorganizes criteria to reduce ambiguity and improve alignment with current practice and external (Medicare) guidance.
The policy specifically calls out overnight oximetry and related limited monitoring as not medically necessary when used for OSA screening or routine diagnosis. Other non-covered screening applications and situations where simplified monitoring is insufficient to establish or exclude OSA are also identified to prevent inappropriate reliance on limited testing modalities.
Actigraphy used alone is considered not medically necessary for the diagnosis of obstructive sleep apnea. The policy also lists other diagnostic modalities considered experimental or investigational for OSA diagnosis such as acoustic pharyngometry or SNAP testing with fewer than three channels, cephalographic x-rays (except where needed for oral appliance or surgical planning), TMJ/sella x-rays, laryngeal studies, sonography, static charge sensitive bed, tomographic x-ray, and limited daytime 'PAPNap' studies (CPT 95807).
CPT 95807 and use of polysomnography for chronic insomnia are noted as not medically necessary in the policy. The document enumerates CPT descriptors and highlights that certain CPT-coded procedures (including attended short daytime PAP desensitization studies) are excluded from coverage when performed for non-covered indications.
The policy reiterates that polysomnography or MSLT should not be used for the listed non-covered indications (for example chronic insomnia, certain preoperative assessments without clinical suspicion of OSA, or evaluation of chronic lung disease when oximetry suffices). These not-covered situations are intended to limit testing to circumstances where results will meaningfully affect clinical management.
To reduce inappropriate approvals the policy removed ambiguous phrases and clarified criteria (for example deleting a reference to current APAP use in certain criteria). These clarifications narrow prior ambiguity and may change prior authorization outcomes if documentation does not meet the revised, explicit requirements.
Provider Actions, Authorization, and Documentation Requirements
Prior authorization / procedure requirements
HSAT and attended PSG, split-night, and in‑lab PAP titration (including full-night 95811) are medically necessary only when the policy’s specific diagnostic and comorbidity criteria are met. Multiple-night HSAT may be administered at the ordering clinician’s discretion but results must be aggregated into a single report and reported as one diagnostic test.
- HSAT meets medical necessity only when all HSAT criteria (A–D) are satisfied.
- Multiple-night HSAT tests should be aggregated into one report and reported as a single HSAT procedure.
HNS pre-implantation sleep study requirement
Prior to hypoglossal nerve stimulation (HNS) implantation, a diagnostic attended sleep study (PSG) or HSAT performed for HNS candidacy is required when the policy’s HNS criteria are met (e.g., BMI <35 kg/m2, AHI 15–65 events/hr, predominantly obstructive events, and documented CPAP failure or intolerance).
- HNS candidacy testing may be PSG or HSAT when the listed adult criteria are satisfied.
- Adolescent (13–18 with Down syndrome) HNS criteria require in‑lab full‑night PSG and the pediatric-specific requirements in the policy.
Home Sleep Testing coverage conditions
Home sleep testing is covered only when performed in conjunction with a comprehensive sleep evaluation in patients with a high pretest probability of moderate to severe OSA, and is not covered for patients with specified comorbidities or for non‑OSA indications.
- HSAT is limited to diagnosis of OSA and covered only for patients without excluded comorbidities (e.g., moderate–severe pulmonary disease, neuromuscular disease, or congestive heart failure).
- The physician performing HSAT must have sufficient training and experience to reliably perform and interpret the service.
Program-specific coverage source
For DSNP members apply Medicare coverage criteria first; for managed Medicaid members follow the guideline beginning on page 1 of this policy when determining coverage and billing.
- DSNP: Medicare coverage criteria (CMS guidance) govern coverage; if not fully approved under Medicare, the plan’s guidelines are used.
- Managed Medicaid: apply the guidelines beginning on page 1 of this document.
Prior authorization for in-facility titration and HNS-related testing
Prior authorization is required per policy for in‑facility full‑night PAP titration and re‑titration (e.g., CPTs 95783, 95811) and for diagnostic testing when used to determine HNS candidacy; documentation must meet the policy’s criteria to support approval.
Titration sequence
Unattended APAP (HCPCS E0601) is appropriate only if attended titration criteria are not met; attended titration is preferred when patients have comorbidities or significant oxygen desaturation documented on diagnostic testing.
- Unattended APAP is allowed only when A (confirmed OSA) is met and B, C, and D (oxygen desaturation criteria, comorbid conditions, APAP failure/intolerance) are not present.
- Attended titration is required when specific comorbidities or desaturation thresholds are present.
CPAP trial required for HNS candidacy
Before evaluation for HNS implantation, document a prior CPAP trial demonstrating failure or intolerance per policy definitions (e.g., residual AHI ≥5 with objective adherence or intolerance defined by <4 hours/night on 5 nights/week or CPAP return).
- CPAP failure: residual AHI >15 despite CPAP usage (HNS adult criteria) or residual AHI ≥5 with adequate adherence for APAP failure definition in titration criteria.
- CPAP intolerance: objective evidence of <4 hours/night on 5 nights/week or CPAP returned, with documentation of shared decision‑making.
Split-night alternative
A facility-based split‑night study may substitute for separate diagnostic and titration nights when a positive diagnostic result is established in the first part of the night and CPAP titration is carried out for >3 hours with elimination or near‑elimination of respiratory events.
- Positive OSA criteria for split‑night use AHI/RDI thresholds (≥15 with ≥30 events, or 5–14 with ≥10 events plus documented symptoms/comorbidities).
- CPAP titration during the same night must be >3 hours and demonstrate resolution or near resolution of events.
Actigraphy payment
Actigraphy may be recorded as part of a sleep test but will not be reimbursed as a separate payable service.
- Actigraphy measures limb movement and, when included within a sleep study, is considered ancillary and not payable separately.
Step therapy
No step therapy requirements are specified in this document section; the policy does not impose additional staged treatment mandates beyond the stated titration and trial requirements.
- The policy describes titration sequence and APAP/attended titration conditions but does not require a formal step‑therapy program beyond those clinical requirements.
Ordering and reporting requirements
Diagnostic testing must be ordered by a licensed physician or advanced practice provider and reviewed/interpreted by a board‑certified sleep physician; if HSAT is administered over multiple nights results should be combined into a single report.
- Orders/referrals and interpretation must come from appropriately licensed/certified clinicians.
- Multiple‑night HSAT recordings must be aggregated into one report for interpretation.
Documentation required to support medical necessity
Maintain documentation to support medical necessity including physician history and physical, procedure notes, treatment plan, diagnostic study reports, and device/trial records; if prior testing is unavailable, physician attestation may be accepted to support the request.
- Required documentation: physician history & physical, physician procedure note, treatment plan, EEG study (if relevant), and polysomnography/sleep study report.
- If prior diagnostic tests are unavailable, a physician attestation may be accepted to justify the requested test.
Documentation requirements
Keep attending physician orders/referrals and clinical documentation that justify the signs, symptoms, or complaints prompting diagnostic testing; sleep clinics must maintain certification and physician direction as specified by CMS guidance.
- Maintain orders/referrals and documentation of symptoms/complaints supporting diagnostic testing.
- Sleep centers must keep accreditation/certification documentation and physician direction available upon request.
Support clinical indication
Clinical documentation must explicitly show that the indication for PSG or MSLT is not one of the policy’s listed non‑covered situations (e.g., chronic insomnia, preoperative evaluation without suspicion of OSA, screening asymptomatic patients).
- Before ordering PSG/MSLT, document how the patient’s presentation does not fall into any of the nine explicit exclusions listed in the policy.
- Requests for testing for employer/government mandates must still meet the policy’s medical necessity criteria to be approved.
Document clinical rationale for chosen diagnostic modality
Document the clinical rationale for the chosen diagnostic modality (PSG vs HSAT) and ensure records support the policy’s updated criteria for in‑facility testing, titration, and HNS candidacy — including pediatric‑specific rationales where applicable.
- For HNS candidacy note whether PSG or HSAT was used and provide documentation meeting the HNS criteria.
- For pediatric testing, document the specific pediatric indication that justifies the modality choice per the policy additions.
Common denial triggers
Common denial triggers include use of overnight oximetry for OSA diagnosis or screening and requests for PSG/HSAT for listed non‑covered indications; ensure documentation addresses these exclusions to avoid denials.
- Overnight oximetry is not medically necessary for OSA screening or diagnosis.
- PSG/HSAT requests for chronic insomnia, circadian rhythm disorders, snoring without daytime sleepiness, or screening asymptomatic patients are likely to be denied.
Diagnostic testing for CDL or other government license purposes
Diagnostic testing performed solely for CDL or other government license purposes (CPTs 95808, 95810, 95811) will be denied unless the patient otherwise meets the policy criteria for in‑facility or home testing.
- Testing for licensing without clinical signs/symptoms meeting the policy is not medically necessary and will be denied.
Denial risk triggers
HSAT is not covered for patients with specific comorbidities (e.g., moderate–severe pulmonary disease, neuromuscular disease, or congestive heart failure); requests for HSAT in these populations risk denial.
- Home testing is limited to OSA diagnosis and excluded in patients with the listed comorbid medical conditions.
- If comorbidities are present, an attended PSG is the appropriate modality and HSAT requests may be denied.
Not covered diagnostic indications
Polysomnography or MSLT is not covered for the policy’s listed indications (for example: diagnosis of chronic insomnia, preoperative evaluation without suspicion of OSA, chronic lung disease without OSA symptoms, uncomplicated parasomnias clearly diagnosed, epilepsy without sleep complaints, circadian rhythm disorders).
- Review the nine explicit not‑covered situations in the policy before ordering PSG or MSLT.
- Document the clinical rationale if there is any question that the patient’s presentation may fall into an exclusion.
Clarified criteria may lead to denials if documentation absent
The policy clarifies and tightens criteria to reduce inappropriate approvals; failure to supply documentation that meets the clarified requirements (e.g., removed references to current APAP use) may result in denials.
- Changes were made to remove ambiguous language; providers should ensure documentation precisely matches the updated criteria.
- Requests lacking documentation aligned to the clarified criteria are at higher risk for denial.
Coding, Thresholds, and Key Clinical Metrics
| E0601 | APAP device (used for unattended titration) |
| 95782 | Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist. |
| 95783 | Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi- level ventilation, attended by a technologist. |
| 95800 | Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time. |
| 95801 | Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (e.g., by airflow or peripheral arterial tone). |
| 95803 | Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording). |
| 95782 | Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist. |
| 95783 | Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of CPAP or bi-level ventilation, attended by a technologist. |
| 95800 | Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time. |
| 95801 | Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (e.g., by airflow or peripheral arterial tone). |
| 95803 | Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording). |
| 95805 | Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation. |
| 95806 | Sleep study, unattended, simultaneous recording of heart rate, oxygen saturation, respiratory airflow, and respiratory effort. |
| 95807 | Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist (Not medically necessary). |
| 95808 | Polysomnography; any age, sleep staging with 1 - 3 additional parameters of sleep, attended by a technologist. |
| 95810 | Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist. |
| 95811 | Polysomnography; age 6 or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level. |
| G0398 | Home sleep study test (HST) with type II portable monitor, unattended; minimum of 7 channels: EEG, EOG, EMG, ECG/heart rate, airflow, respiratory effort and oxygen saturation. |
| G0399 | Home sleep test (HST) with type III portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate and 1 oxygen. |
| G0400 | Home sleep test (HST) with type IV portable monitor, unattended; minimum of 3 channels. |
Definitions and Device Classifications
Background and Scope
Sleep studies are used to diagnose sleep disorders and to assess treatment needs and efficacy. Initial testing for suspected moderate-to-severe obstructive sleep apnea may be performed with PSG or HSAT when clinical risk and policy criteria are met. The policy separates guidance for adults and children, recognizing different indications and that HSAT is generally not appropriate for those <18 years; diagnostic testing must be ordered by an appropriate licensed provider and interpreted by a board-certified sleep physician.
Coding and Billing Notes (Ancillary)
Actigraphy included in sleep test is not separately payable
Actigraphy is part of the sleep study when measured during testing and will not be reimbursed separately; billers should not submit a separate claim for actigraphy when included in a sleep test.
Government/CDL testing denied without meeting policy criteria
Diagnostic testing provided solely to satisfy CDL or other government licensing requirements will be denied unless the patient otherwise meets the policy criteria for the requested in‑facility or home test.
Policy Revision History and Material Changes
Modified HNS candidacy testing to explicitly allow either polysomnography (PSG) or Home Sleep Apnea Test (HSAT); added diagnostic evaluation criteria for HNS implantation in members with Down syndrome younger than 18 years; added pediatric indications for hypersomnia, suspected narcolepsy (with MSLT), suspected restless leg syndrome, and suspected periodic limb movement disorder; reorganized pediatric in-facility full-night PAP titration into separate initial and re-titration sections; and divided the medical guideline content into separate adult and pediatric sections.
Added HSAT as an acceptable test for determining HNS candidacy in the Diagnostic Testing for Hypoglossal Nerve Stimulation Implantation section and removed the 2–6 month timing restriction in post-diagnostic HNS testing; updated references and removed the word 'Acute' from comorbid medical conditions.
Updated repeat attended titration and pediatric split-night study criteria for clarity (moved oxygen saturation criteria, removed phrase about current APAP therapy, added a criterion for treatment-emergent central sleep apnea and failed split-night titration); clarified MSLT criteria; and added HSAT to HNS diagnostic criteria.
This policy is reviewed on an annual basis. The document effective date is 2026-08-01 and the next scheduled review is 2027-06-01, consistent with the guideline update history and annual review cycle noted in the policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.